| Patents for C12N 15 - Mutation or genetic engineering; Dna or rna concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor (402,210) |
|---|
| 01/27/2004 | CA2105644C Resurfacing of rodent antibodies |
| 01/27/2004 | CA2021489C Methods and compositions for chromosome-specific staining |
| 01/27/2004 | CA2002607C Natural killer stimulatory factor |
| 01/26/2004 | CA2413275A1 Somatic pluripotent cells |
| 01/23/2004 | CA2433473A1 Fluorescent hybridization probes with reduced background |
| 01/22/2004 | WO2004008361A1 Information processing system using base sequence relevant information |
| 01/22/2004 | WO2004008149A1 Diagnostic and therapeutic use of a rab family gtp-binding protein for neurodegenerative diseases |
| 01/22/2004 | WO2004008147A2 Diagnosis and prevention of cancer cell invasion |
| 01/22/2004 | WO2004007772A1 Antisense modulation of cellular inhibitor of apoptosis-2 expression |
| 01/22/2004 | WO2004007770A2 Method for diagnosis of intestinal-type gastric tumors |
| 01/22/2004 | WO2004007767A2 Serrs reactive particles |
| 01/22/2004 | WO2004007766A1 Nucleic acid amplification method |
| 01/22/2004 | WO2004007764A2 Chromosome 3, 5 and 11 genes involved in premature canities |
| 01/22/2004 | WO2004007753A2 Transgenic non-human mammals expressing a reporter nucleic acid under the regulation of androgen response elements |
| 01/22/2004 | WO2004007748A2 Deprotection and purification of oligonucleotides and their derivatives |
| 01/22/2004 | WO2004007742A2 Chromosome 6 and 9 genes involved in premature canities |
| 01/22/2004 | WO2004007736A1 Electroporation method including the use of depressurization/pressurization |
| 01/22/2004 | WO2004007735A1 Methods of making viral particles having a modified cell binding activity and uses thereof |
| 01/22/2004 | WO2004007734A1 Her-2/neu dna vaccine having anti-cancer activity |
| 01/22/2004 | WO2004007733A1 Transgenic expression constructs and methods for increasing the vitamin e content in plant organisms |
| 01/22/2004 | WO2004007732A1 Cloning and characterization of a lipoxygenase from phaeodactylum tricornutum |
| 01/22/2004 | WO2004007731A1 Transgenic expression constructs and methods for increasing the vitamin e content in plant organisms |
| 01/22/2004 | WO2004007730A1 Method for modifying plants |
| 01/22/2004 | WO2004007729A1 Transcriptional control element, chimeric constructs and uses therefor |
| 01/22/2004 | WO2004007727A1 Use of a gene for increasing the oil content in plants |
| 01/22/2004 | WO2004007726A2 Brachyspira hyodysenteriae vaccine |
| 01/22/2004 | WO2004007725A1 Polypeptide of streptococcus pyogenes |
| 01/22/2004 | WO2004007724A1 Method of transporting protein to mitochondria |
| 01/22/2004 | WO2004007723A2 Genes |
| 01/22/2004 | WO2004007722A2 Transgenic animal expressing alzheimer’s tau protein |
| 01/22/2004 | WO2004007721A1 Conjugate for double-stranded rna sequence releasing and methods thereof |
| 01/22/2004 | WO2004007720A2 Treatment of proliferative disorders |
| 01/22/2004 | WO2004007718A2 Rna-interference by single-stranded rna molecules |
| 01/22/2004 | WO2004007717A1 Proteomic screen to identify disease-related biological molecules and inhibitors thereto |
| 01/22/2004 | WO2004007716A1 Method of isolating gpcr gene and novel gpcr gene |
| 01/22/2004 | WO2004007715A1 Method of transferring mutation into target nucleic acid |
| 01/22/2004 | WO2004007712A2 Modulating developmental pathways in plants |
| 01/22/2004 | WO2004007710A1 Solid support having electrostatic layer and use thereof |
| 01/22/2004 | WO2004007709A2 Production of polyketides |
| 01/22/2004 | WO2004007708A1 Modulation of cytochrome p450 reductase activity |
| 01/22/2004 | WO2004007706A1 Plant nucleotide-sugar pyrophosphatase/phosphodiesterase (nppase), method of obtaining same and use of same in the production of assay devices and in the production of transgenic plants |
| 01/22/2004 | WO2004007705A1 Nucleotide sequences that encode deregulated phosphoglycerate dehydrogenases of coryneform bacteria and method for producing l-serine |
| 01/22/2004 | WO2004007703A1 Replicability virus which can express anti-tumour antibody with high efficiency and the use of it |
| 01/22/2004 | WO2004007702A2 Modulators of chloride intracellular channel 1 protein signaling ____________________________________________________________ |
| 01/22/2004 | WO2004007697A2 Methods of implanting mesenchymal stem cells for tissue repair and formation |
| 01/22/2004 | WO2004007695A2 Lactobacilli expressing biologically active polypeptides and uses thereof |
| 01/22/2004 | WO2004007694A2 High efficiency germline transformation system |
| 01/22/2004 | WO2004007691A2 Herbicide-resistant plants, and polynucleotides and methods for providing same |
| 01/22/2004 | WO2004007687A2 Methods to construct multimeric dna and polymeric protein sequences as direct fusions or with linkers |
| 01/22/2004 | WO2004007686A2 Methods and transgenic mouse model for identifying and modulating factors involved in the production of reactive oxygen intermediates |
| 01/22/2004 | WO2004007684A2 Synthetic tag genes |
| 01/22/2004 | WO2004007679A2 Dendritic cell pontentiation |
| 01/22/2004 | WO2004007678A2 Codon optimized synthetic plasmids |
| 01/22/2004 | WO2004007670A2 RECOMBINANT TYPE II RESTRICTION ENDONUCLEASES, MmeI AND RELATED ENDONUCLEASES AND METHODS FOR PRODUCTING THE SAME |
| 01/22/2004 | WO2004007668A2 Improved transporters and their uses |
| 01/22/2004 | WO2004007664A2 Nucleic acid vectors |
| 01/22/2004 | WO2004007663A2 Gene expression using metal ion dependent repressor/operator tandems |
| 01/22/2004 | WO2004007660A2 Novel hsf transcription factors and use thereof in transgenic plants |
| 01/22/2004 | WO2004007556A1 Expression of hydrophobic proteins |
| 01/22/2004 | WO2004007553A1 Antibodies anti-c5 component of the complement system and their use |
| 01/22/2004 | WO2004007551A1 Splice variant cannabinoid receptor (cb1b) |
| 01/22/2004 | WO2004007550A1 Mcam inhibitors |
| 01/22/2004 | WO2004007547A2 Truncated tau proteins |
| 01/22/2004 | WO2004007546A1 Mutant proteins and use thereof for the manufacture of medicaments and the treatment of humans or animals suffering from conformational diseases |
| 01/22/2004 | WO2004007542A1 Variants of the house dust mite allergen der f2 |
| 01/22/2004 | WO2004007541A1 STREPTOCOCCUS PNEUMONIAE PBP2x MINI-PROTEIN AND USES THEREOF. |
| 01/22/2004 | WO2004007539A2 Hsp70 from arthrobacter |
| 01/22/2004 | WO2004007537A2 Modified adenoviral fiber with ablated to cellular receptors |
| 01/22/2004 | WO2004007536A2 Interactions of the epstein-barr virus protein ebna1, and uses thereof |
| 01/22/2004 | WO2004007531A2 Activated checkpoint therapy and methods of use thereof |
| 01/22/2004 | WO2004007525A2 Immunogenic composition comprising a fusion protein and a saponin adjuvant |
| 01/22/2004 | WO2004007078A1 Lateral flow assay device and method |
| 01/22/2004 | WO2004006955A1 Super humanized antibodies |
| 01/22/2004 | WO2004006949A1 Methods and compositions for regulation of mammalian hair growth |
| 01/22/2004 | WO2004006941A1 Antisense compounds, methods and compositions for treating ngal-related inflammatory disorders |
| 01/22/2004 | WO2004006891A2 Delivery system for pharmaceutical agents |
| 01/22/2004 | WO2004006866A2 Antifungal therapeutic targets |
| 01/22/2004 | WO2004006855A2 Rhodococcus equi mutants and vaccines comprising same |
| 01/22/2004 | WO2004006839A2 Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use |
| 01/22/2004 | WO2004006678A1 Spliceosome mediated rna trans-splicing for correction of skin disorders |
| 01/22/2004 | WO2004006667A2 Methods for the regeneration and transformation of cotton |
| 01/22/2004 | WO2004006662A1 DISEASE MODEL ANIMAL CARRYING FOREIGN PPARα GENE TRANSFERRED THEREINTO AND USE THEREOF |
| 01/22/2004 | WO2004006659A1 High yielding soybean plants with increased seed protein plus oil |
| 01/22/2004 | WO2004006658A1 Method of constructing caffeineless coffee plant by genetic recombination |
| 01/22/2004 | WO2004006657A1 Transgenic plants used as a bioreactor system |
| 01/22/2004 | WO2004006656A2 Transgenic bioluminescent plants |
| 01/22/2004 | WO2004006655A2 Nuclear fertility restorer genes and methods of use in plants |
| 01/22/2004 | WO2003097665A3 Mid 241 receptor, a novel g-protein coupled receptor |
| 01/22/2004 | WO2003095640A3 Transgenic rat as animal model for human huntingdon's disease |
| 01/22/2004 | WO2003090778A3 Dna vaccine combined with an inducer of tumor cell apoptosis |
| 01/22/2004 | WO2003089906A3 Functionalized nanoparticles and methods of use |
| 01/22/2004 | WO2003087369A3 Ribozyme capable of specifically cleaving mmp-13 |
| 01/22/2004 | WO2003086289A3 Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
| 01/22/2004 | WO2003078577A9 Cloning of cytochrome p450 genes from nicotiana |
| 01/22/2004 | WO2003076561A3 Recombinase fusion protein with enhanced cellular uptake |
| 01/22/2004 | WO2003073843A3 Inbred embryonic stem-cell derived mice |
| 01/22/2004 | WO2003070933A3 Process of cell electrofusion |
| 01/22/2004 | WO2003068966A3 REGULATION OF HUMAN Ca2+-PERMEABLE NONSELECTIVE CATION CHANNEL |
| 01/22/2004 | WO2003067213A3 Modulation of sulfate permease for photosynthetic hydrogen production |
| 01/22/2004 | WO2003066852A3 Plant growth modulation by drl1 and other proteins of the elongator complex |